SCHEMBL4445549

SCHEMBL4445549

SCCCCCCCCCCc1cccs1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.57
TSHR P16473 2/20 0.50
ADRA2A P08913 3/20 0.43
ADRA2B P18089 3/20 0.43
ADRA2C P18825 3/20 0.43
NPC1 O15118 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
RAB9A P51151 1/20 0.39
CYP2C19 P33261 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1742598 1.00 TAAR1 (0.57) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL919512 1.00 TAAR1 (0.57) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL31357205 1.00 TAAR1 (0.57) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL920878 0.98 TAAR1 (0.59) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL920267 0.91
SCHEMBL6734915 0.89 TAAR1 (0.70) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL7116263 0.89 TAAR1 (0.70) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL8571535 0.89 TAAR1 (0.70) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL20146704 0.87 TAAR1 (0.73) TAAR1TSHRADRA2AADRA2BADRA2C
SCHEMBL268567 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4447944-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES THE PENN STATE RESEARCH FOUNDATION (US) 2024-10-23 EP disclosed
US-20240335540-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES PENN STATE RES FOUND (US) 2024-10-10 US disclosed
CN-118613287-A Compositions and methods for targeted delivery of therapeutic and/or diagnostic substances 宾夕法尼亚州立大学研究基金会 2024-09-06 CN disclosed
WO-2023114466-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES THE PENN STATE RESEARCH FOUNDATION (US) 2023-06-22 WO disclosed
US-7560731-B2 Organic electronic device and method for manufacturing the same PANASONIC CORPORATION (JP) 2009-07-14 US disclosed
US-7259389-B2 Organic electronic device and method for manufacturing the same MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2007-08-21 US disclosed
US-20070085076-A1 Organic electronic device and method for manufacturing the same MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2007-04-19 US disclosed
US-20050145839-A1 Organic electronic device and its manufacturing method PANASONIC CORPORATION (JP) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335540-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES PAICS, CD47, CA13 TAAR1 2552/4885TSHR 3884/4885ADRA2A 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.